Mar 14, 2026, 12:00 AM
Findings of randomized clinical trial support use of adjuvant pembrolizumab in high-risk stage II melanoma
Importance: Patients with melanoma are at risk of developing subsequent cutaneous malignant neoplasms, and the effect of prior immunotherapy is unknown. Objective: To analyze new skin cancers in …
Transcription factor HOXD13 drives melanoma growth and immune evasion
Ultraviolet (UV)-induced DNA mutations generate genetic drivers of cutaneous melanoma and numerous neoantigens that can trigger anti-tumor immunity. Melanoma cells must therefore rapidly evade immune …
Read more about 'Transcription factor HOXD13 drives melanoma growth and immune evasion'...
Study establishes a pan-skin cancer immune remodelling framework, providing a foundation for biomark
Background: Skin cancers, including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), cutaneous melanoma (CM) and acral melanoma (AM), exhibit profound heterogeneity in clinical behaviour and…
Formative research to inform an Australian innovative mass-reach national skin cancer prevention campaign
Issue Addressed: With high skin cancer rates, Australia faces challenges in encouraging young people to think differently about their sun protection behaviours, particularly in an evolving media envir…
